Numerical methods for the evaluation of individual bioequivalence criteria

被引:1
|
作者
Kimanani, EK [1 ]
Lavigne, J [1 ]
Potvin, D [1 ]
机构
[1] Phoenix Int Life Sci, Biometr & Pharmacokinet R&D, Phoenix Int Life Sci, Quebec City, PQ H4R 2N6, Canada
关键词
D O I
10.1002/1097-0258(20001030)19:20<2775::AID-SIM545>3.3.CO;2-7
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The evaluation of individual bioequivalence (IBE) by bootstrap resampling using common statistical software, for example SAS, is extremely time consuming. In this article, an estimation procedure that can be implemented in a high level language with the same degree of accuracy as SAS is described. The necessary parameter estimating equations under both least square (LSE) and restricted maximum likelihood (REML) methods are given. The algorithms used to numerically compute these values are outlined and tested in FORTRAN, on several simulated data sets and shown to reproduce SAS results with at least 10(-3) precision. More importantly, the REML bootstrap algorithm reduces the time taken in SAS by a factor of 20. Secondary results indicate that LSE and REML parameter estimates are similar for mild unbalancedness. PROC MIXED, with unstructured (UN) and compound symmetry heterogeneous (CSH) variance structures give the same results except when the subject-by-treatment interaction variance, sigma(D)(2), is 0 in which case CSH significantly overestimates sigma(D)(2) and underestimates the within-treatment variances. It is concluded that bootstrap evaluation of IBE is efficiently done using either the LSE or REML algorithm in FORTRAN. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:2775 / 2795
页数:21
相关论文
共 50 条
  • [1] REVIEW OF METHODS AND CRITERIA FOR THE EVALUATION OF BIOEQUIVALENCE STUDIES
    PABST, G
    JAEGER, H
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (01) : 5 - 10
  • [2] Comprehensive criteria for population and individual bioequivalence
    Ghosh, K
    Hesney, M
    Sarkar, S
    Thiyagarajan, B
    AMERICAN STATISTICAL ASSOCIATION - 1996 PROCEEDINGS OF THE BIOPHARMACEUTICAL SECTION, 1996, : 77 - 81
  • [3] A METHOD FOR THE EVALUATION OF INDIVIDUAL BIOEQUIVALENCE
    ENDRENYI, L
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1994, 32 (09) : 497 - 508
  • [4] A PROCEDURE FOR THE EVALUATION OF INDIVIDUAL BIOEQUIVALENCE
    ENDRENYI, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 221 - 221
  • [5] Statistical evaluation of individual bioequivalence
    Liu, JP
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1998, 27 (06) : 1433 - 1451
  • [6] Cyclosporine: The case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets
    Barr, WH
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (3A) : 25S - 30S
  • [7] Bioequivalence of topical dermatological dosage forms - Methods of evaluation of bioequivalence
    Shah, VP
    Flynn, GL
    Yacobi, A
    Maibach, HI
    Bon, C
    Fleischer, NM
    Franz, TJ
    Kaplan, SA
    Kawamoto, J
    Lesko, LJ
    Marty, JP
    Pershing, LK
    Schaefer, H
    Sequeira, JA
    Shrivastava, SP
    Wilkin, J
    Williams, RL
    PHARMACEUTICAL RESEARCH, 1998, 15 (02) : 167 - 171
  • [8] A nearly unbiased test for individual bioequivalence problems using probability criteria
    Wang, WZ
    Hwang, JTG
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2001, 99 (01) : 41 - 58
  • [9] Bioequivalence of Topical Dermatological Dosage Forms-Methods of Evaluation of Bioequivalence
    Vinod P. Shah
    Gordon L. Flynn
    Avraham Yacobi
    Howard I. Maibach
    Charles Bon
    Nicholas M. Fleischer
    Thomas J. Franz
    Stanley A. Kaplan
    Jeff Kawamoto
    Lawrence J. Lesko
    Jean-Paul Marty
    Lynn K. Pershing
    Hans Schaefer
    Joel A. Sequeira
    Surendra P. Shrivastava
    Jonathan Wilkin
    Roger L. Williams
    Pharmaceutical Research, 1998, 15 : 167 - 171
  • [10] New bioequivalence studies: Individual bioequivalence and population bioequivalence
    Nakai, K
    Fujita, M
    Ogata, H
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2000, 120 (11): : 1201 - 1208